The advanced therapies sector is growing exponentially. The Alliance for Regenerative Medicine (ARM) reports that the sector raised $23.1 billion in 2021 – a 16% year-over-year increase. That figure includes $1.9 billion in private financing and $9.8 billion in venture funding.

This white paper is based on a panel discussion sponsored by Precision ADVANCE at the 2021 Meeting on the Mesa conference and features insights from C-suite leaders on the current CGTx investment landscape, technology innovations, talent shortage and the evolution of reimbursement payment models.

• Anshul Mangal: President (Project Farma & Precision ADVANCE)
• R.A. Session II: President, Founder and CEO (Taysha Gene Therapies)
• Palani Palaniappan: EVP and CTO (Aruvant Sciences)
• Derrell Porter: Founder and CEO (Cellevolve Bio)
• Claudia Zylberberg: Founder and Executive Chair (Akron Bio)
• Phil Cyr: SVP (Precision Value & Health)

Read Now!

Advances in stem cell technology, combined with the increasing prevalence of chronic diseases, are driving rapid growth in the regenerative medicine category, which is predicted to generate $39.33 billion in revenue by 2023.

(more…)

The regenerative medicine category is predicted to generate $39.33 billion in revenue by 2023, with the fastest growth expected in cell therapy.

(more…)

“There’s a little over 1,200 clinical trials worldwide, and about half of those are in the US. Over 100 of those are in phase III, so we’re getting really close to getting more approved.”

(more…)

Project Farma experts Lesley Davis, Andrew Doppstadt, and Phil Baratta recently participated in the publication of an ISPE Guide titled, “Advanced Therapy Medicinal Products – Autologous Cell Therapy”.

(more…)

A 2018 study by Deloitte suggested that more than 2.4 million manufacturing jobs in the US would remain unfilled in 2028 because of the widening – and often generational – skills gap.

(more…)

Is “flexible manufacturing” just another empty buzz concept concocted by the biopharma equipment marketing community, or does it demonstrate real benefit? Business of Biotech Podcast: Episode 69, “Foundations of Flexible Manufacturing” features insights from Tony Khoury (EVP of Project Farma) and Brian Winstead (Senior Director, Facilities & Engineering at Sarepta Therapeutics) on what flexible manufacturing means, when it works and when it doesn’t.

(more…)